Topical Minoxidil Foam Composition for Crystal Control and Skin Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing Minoxidil formulations face challenges with crystal formation, organoleptic properties, and safety concerns, leading to undesirable effects like irritation and reduced patient adherence due to high surfactant concentrations and viscosity, which affect the drug's solubility and systemic absorption.
Innovation Solution
A topical foamable pharmaceutical composition comprising Minoxidil, a water-miscible organic solvent, organic acid, amphoteric and non-ionic surfactants, antioxidant, and water, formulated to inhibit crystal formation and provide a pleasant tactile feeling, with specific ratios to enhance solubility and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high concentrations of ethanol and/or propylene glycol are used to ensure Minoxidil solubility, then drug solubility is improved, but organoleptic properties and patient adherence deteriorate due to irritation and unpleasant sensation
Solution Approach 1:
The patent changes the chemical parameters of the formulation by introducing organic acids (lactic acid, glycolic acid, or salicylic acid) at specific concentrations (0.1-10% w/v) to alter the solubility characteristics and reduce irritation. This parameter change allows maintaining Minoxidil solubility while improving organoleptic properties and reducing skin irritation compared to conventional high ethanol/propylene glycol formulations
Solution Approach 2:
The patent creates a composite formulation system combining Minoxidil with specific organic acids and co-solvents in defined ratios. This composite approach allows the formulation to achieve both solubility and reduced irritation by leveraging the synergistic effects of multiple components rather than relying on high concentrations of单一 solvent
2Ease of operation
If high surfactant concentrations are used to improve foam stability and application, then ease of operation is improved, but harmful effects increase due to irritation and reduced patient adherence
Solution Approach 1:
The patent optimizes surfactant concentration parameters to specific ranges (0.1-5% w/v) and combines them with organic acids at controlled concentrations. This parameter optimization allows achieving adequate foam stability for easy application while minimizing skin irritation and improving patient adherence compared to high surfactant formulations
3Quantity of substance
If high viscosity formulations are used to improve drug retention, then drug retention is improved, but ease of operation deteriorates due to difficult application and spread
Solution Approach 1:
The patent adjusts viscosity parameters by controlling the concentration of organic acids (0.1-10% w/v) and co-solvents to achieve an optimal balance. The formulation maintains sufficient viscosity for drug retention while ensuring easy application and spreadability, avoiding the excessive viscosity problems of conventional formulations
4Reliability
If Minoxidil is formulated to achieve good skin permeation, then therapeutic efficiency is improved, but systemic exposure increases leading to adverse effects
Solution Approach 1:
The patent enhances local quality at the application site by using organic acids and optimized surfactant systems that improve drug penetration into the scalp and hair follicles locally. This allows achieving therapeutic efficiency at the target site while maintaining lower overall systemic exposure through localized enhanced delivery rather than requiring high overall concentrations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively inhibits Minoxidil crystal formation, maintains drug solubility, and ensures greater retention in the epidermis and dermis, providing a pleasant application experience while minimizing systemic exposure.
Implementation Method 1
The organic acid...acts to increase the solubility of the Minoxidil in the formulation
Implementation Method 2
containing...at least one surfactant system...The present invention...provides a composition in the form of a foamable solution
Implementation Method 3
Minoxidil has low water solubility (2.2 mg/mL), moderate ethanol solubility (29 mg/mL) and high propylene glycol solubility (75 mg/mL)
Data Source
AI summary
A TOPICAL FOAMABLE PHARMACEUTICAL COMPOSITION wherein the pharmaceutical composition is a solution includes (a) 1 to 7% (mass/volume) Minoxidil or the pharmaceutically acceptable salt thereof; (b) 1 to 50% (mass/volume) water-miscible organic solvent: (c) content of an organic acid in an equimolar amount to that of the drug Minoxidil: (d) 1 to 30% (mass/volume) of at least one co-solvent: (e) 2 to 10% (mass/volume) of at least one amphoteric surfactant; (f) 1 to 5% (mass/volume) of at least one nonionic surfactant; (g) 0.1 to 1% (mass/volume) of at least one antioxidant; and (h) water.